title: What we now know about the new oral anticoagulants and their reversal.
authors.affiliation: School of Pharmacy, LECOM, Bradenton, Florida.
authors.forename: Kathryn
authors.initials: K
authors.lastname: Samai
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects*; D000991:Antithrombins / Q000008:administration & dosage / Q000009:adverse effects; D000069604:Dabigatran / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D061214:Patient Safety; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D014481:United States; D014486:United States Food and Drug Administration; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects; D014947:Wounds and Injuries / Q000188:drug therapy* / Q000451:nursing
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D014859:Warfarin; D000069604:Dabigatran